Urogen Pharma Stock Last Dividend Paid
| URGN Stock | USD 11.35 0.12 1.05% |
UroGen Pharma fundamentals help investors to digest information that contributes to UroGen Pharma's financial success or failures. It also enables traders to predict the movement of UroGen Stock. The fundamental analysis module provides a way to measure UroGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to UroGen Pharma stock.
UroGen |
UroGen Pharma Company Last Dividend Paid Analysis
UroGen Pharma's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, UroGen Pharma has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
UroGen Fundamentals
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.29) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 351.31 M | ||||
| Shares Outstanding | 42.2 M | ||||
| Shares Owned By Insiders | 9.17 % | ||||
| Shares Owned By Institutions | 92.26 % | ||||
| Number Of Shares Shorted | 5.77 M | ||||
| Price To Earning | 239.57 X | ||||
| Price To Book | 18.77 X | ||||
| Price To Sales | 5.36 X | ||||
| Revenue | 82.71 M | ||||
| Gross Profit | 56.7 M | ||||
| EBITDA | (63.83 M) | ||||
| Net Income | (102.24 M) | ||||
| Cash And Equivalents | 111.74 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 100.21 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (76.38 M) | ||||
| Short Ratio | 12.42 X | ||||
| Earnings Per Share | (3.02) X | ||||
| Target Price | 39.93 | ||||
| Number Of Employees | 217 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 478.96 M | ||||
| Total Asset | 178.31 M | ||||
| Retained Earnings | (679.35 M) | ||||
| Working Capital | 137.97 M | ||||
| Net Asset | 178.31 M |
About UroGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze UroGen Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UroGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UroGen Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against UroGen Stock
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out UroGen Pharma Piotroski F Score and UroGen Pharma Altman Z Score analysis. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.